Login
$TARS
$78.16 -$2.12 (2.64%) Live

Company Executives

Officer Age In this role 2025 pay Source
Bobak Azamian Also a director
President, Chief Executive Officer and Chairman
48 Not stated $6,617,979
Seshadri Neervannan
Chief Operating Officer
57 Since 2020
6 years
$2,628,172
Aziz Mottiwala
Chief Commercial Officer
48 Since 2020
6 years
Not reported
Bryan Wahl
General Counsel and Secretary
48 Not stated $2,560,205
Dianne Whitfield
Chief Human Resources Officer
49 Since 2021
5 years
Not reported
Elizabeth Yeu-Lin
Chief Medical Officer
47 Since 2024
2 years
Not reported
Neera Clase
Chief Commercial Officer
Title from the Form 4 dated Nov 3, 2026
Not stated Not stated Not reported
Jeffrey Farrow
See Remarks
Title from the Form 4 dated Jun 15, 2026
64 Not stated $2,677,617

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
7 of 7
stated in the proxy; 1 not stated
CEO also chairs the board
Yes
Bobak Azamian
Director Age Independent 2025 pay Source
Bobak Azamian
47 Not stated Paid as CEO
Wendy Yarno
70 Independent Not stated
Andrew Goldberg
43 Independent $310,284
Scott Morrison
67 Independent $316,728
David E.I. Pyott
72 Independent Not stated
Bhaskar Chaudhuri
71 Independent Not stated
Katherine Goodrich
56 Independent $306,728

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 28, 2026
David E.I. Pyott
prior to his appointment to our Board
$25,000

Consulting agreement under which Mr. Pyott served as an advisor to the Company, with annual cash compensation, an option and RSUs

Dr. Azamian
CEO and Chair of the Board of the Company; serves on the board of the private eye care company
$3.9 million
2024 and 2025

Company purchased preferred stock in a private eye care company (April 2024 and December 2025 investments; Dr. Link, a Board member, also serves on that company's board)

With an early clinical-stage private eye care company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support